223 related articles for article (PubMed ID: 28836865)
1. The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.
van Hulst M; Stevanovic J; Jacobs MS; Tieleman RG; Kappelhoff B; Postma MJ
J Med Econ; 2018 Jan; 21(1):38-46. PubMed ID: 28836865
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
van Leent MW; Stevanović J; Jansman FG; Beinema MJ; Brouwers JR; Postma MJ
PLoS One; 2015; 10(8):e0135054. PubMed ID: 26241880
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.
Stevanović J; de Jong LA; Kappelhoff BS; Dvortsin EP; Voorhaar M; Postma MJ
PLoS One; 2016; 11(10):e0163550. PubMed ID: 27776137
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
Wouters H; Thijs V; Annemans L
J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.
Carles M; Brosa M; Souto JC; Garcia-Alamino JM; Guyatt G; Alonso-Coello P
BMC Health Serv Res; 2015 Jul; 15():289. PubMed ID: 26215871
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands.
Bennaghmouch N; de Veer AJWM; Mahmoodi BK; Jofre-Bonet M; Lip GYH; Bode K; Ten Berg JM
Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):127-135. PubMed ID: 30016398
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
Langkilde LK; Bergholdt Asmussen M; Overgaard M
J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
14. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
[TBL] [Abstract][Full Text] [Related]
15. A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS
Kimura T; Igarashi A; Ikeda S; Nakajima K; Kashimura S; Kunitomi A; Katsumata Y; Nishiyama T; Nishiyama N; Fukumoto K; Tanimoto Y; Aizawa Y; Fukuda K; Takatsuki S
J Cardiol; 2017 Jan; 69(1):89-97. PubMed ID: 26947099
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
Vlacho B; Giner-Soriano M; Zabaleta-Del-Olmo E; Roso-Llorach A; García-Sangenís A; Morros-Pedrós R
Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.
Stevanović J; Pompen M; Le HH; Rozenbaum MH; Tieleman RG; Postma MJ
PLoS One; 2014; 9(8):e103974. PubMed ID: 25093723
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
Clemens A; Peng S; Brand S; Brueckmann M; Kansal A; Lim J; Noack H; Sander S; Sorensen S
Am J Cardiol; 2014 Sep; 114(6):849-55. PubMed ID: 25103918
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland.
Pletscher M; Plessow R; Eichler K; Wieser S
Swiss Med Wkly; 2013; 143():w13732. PubMed ID: 23300013
[TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
De Caterina R; John Camm A
Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
